Aktie A3CZBW HUMACYTE, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Humacyte, Inc.

Aktien

A3CZBW

US44486Q1031

HUMA

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 28.06.2024 		% 5 Tage % 1. Jan.
4.8 USD +2.13% Intraday Chart für Humacyte, Inc. -7.16% +69.01%
25.06. Humacyte, Inc. präsentiert positive präklinische Daten für sein biovaskuläres Pankreas (Bvp??) Programm CI
13.06. Humacyte-Insider verkauft Aktien im Wert von $4.520.024, laut einer aktuellen SEC-Einreichung MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Humacyte Presents Positive Preclinical Data for Its BioVascular Pancreas Program
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp??) Program
Humacyte, Inc.(NasdaqGS:HUMA) added to S&P Biotechnology Select Industry Index
Centers for Medicare and Medicaid Services Issues ICD-10-PCS Codes for Humacyte s Human Acellular Vessel
Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
Humacyte Insider Sold Shares Worth $4,520,024, According to a Recent SEC Filing
Humacyte Insider Sold Shares Worth $4,520,024, According to a Recent SEC Filing
Humacyte, Inc. Appoints Keith Anthony Jones as Class III Director
Humacyte Insider Sold Shares Worth $1,561,605, According to a Recent SEC Filing
Humacyte to Present at the Jefferies Global Healthcare Conference
Certain Common Stock of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.
Certain Warrants of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.
Certain Stock Options of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.
Humacyte First Quarter 2024 Financial Results and Business Update
Humacyte to Participate at Upcoming Investor Conferences in May
Humacyte First Quarter 2024 Financial Results and Business Update
Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
Humacyte to Host Virtual KOL Event Hemodialysis Access, a Crossroads of Care, on March 28, 2024
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CZBW Aktie
  4. Nachrichten Humacyte, Inc.
  5. Andere Sprachen